Children with three copies of SMN2 have a greater likelihood of developing SMA type 2 or type 3, but SPR1NT demonstrates that treating three-copy children before the appearance of SMA symptoms essentially allows them to grow and develop as normal children. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.